HUP0201117A3 - Attenuated microorganisms for the treatment of infection - Google Patents

Attenuated microorganisms for the treatment of infection

Info

Publication number
HUP0201117A3
HUP0201117A3 HU0201117A HUP0201117A HUP0201117A3 HU P0201117 A3 HUP0201117 A3 HU P0201117A3 HU 0201117 A HU0201117 A HU 0201117A HU P0201117 A HUP0201117 A HU P0201117A HU P0201117 A3 HUP0201117 A3 HU P0201117A3
Authority
HU
Hungary
Prior art keywords
infection
treatment
attenuated microorganisms
attenuated
microorganisms
Prior art date
Application number
HU0201117A
Other languages
English (en)
Original Assignee
Microscience Ltd Wokingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microscience Ltd Wokingham filed Critical Microscience Ltd Wokingham
Publication of HUP0201117A2 publication Critical patent/HUP0201117A2/hu
Publication of HUP0201117A3 publication Critical patent/HUP0201117A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
HU0201117A 1999-05-10 2000-05-09 Attenuated microorganisms for the treatment of infection HUP0201117A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9910812.8A GB9910812D0 (en) 1999-05-10 1999-05-10 Vaccine composition

Publications (2)

Publication Number Publication Date
HUP0201117A2 HUP0201117A2 (en) 2002-08-28
HUP0201117A3 true HUP0201117A3 (en) 2004-01-28

Family

ID=10853168

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201117A HUP0201117A3 (en) 1999-05-10 2000-05-09 Attenuated microorganisms for the treatment of infection

Country Status (28)

Country Link
US (3) US6756042B1 (hu)
EP (2) EP1702927B1 (hu)
JP (1) JP4583607B2 (hu)
KR (2) KR100680391B1 (hu)
CN (1) CN1177863C (hu)
AP (1) AP1470A (hu)
AT (2) ATE346090T1 (hu)
AU (1) AU763898B2 (hu)
BR (1) BRPI0010418B8 (hu)
CA (1) CA2372553C (hu)
CY (1) CY1107656T1 (hu)
CZ (1) CZ301926B6 (hu)
DE (2) DE60043868D1 (hu)
DK (1) DK1183269T3 (hu)
EA (1) EA004921B1 (hu)
ES (1) ES2277591T3 (hu)
GB (1) GB9910812D0 (hu)
HU (1) HUP0201117A3 (hu)
IL (3) IL146255A0 (hu)
MA (1) MA25411A1 (hu)
MX (1) MXPA01011477A (hu)
NO (1) NO329520B1 (hu)
NZ (1) NZ539260A (hu)
OA (1) OA11940A (hu)
PT (1) PT1183269E (hu)
TR (1) TR200702949T2 (hu)
WO (1) WO2000068261A2 (hu)
ZA (1) ZA200108912B (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ511170A (en) * 1994-12-09 2005-02-25 Imp College Innovations Ltd Administering anitgens for protection against Salmonella infections
AU5860599A (en) * 1998-09-04 2000-03-27 Creatogen Aktiengesellschaft Attenuated salmonella spi2 mutants as antigen carriers
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
GB0105924D0 (en) * 2001-03-09 2001-04-25 Microscience Ltd Promoter
US7449178B2 (en) * 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2008153772A2 (en) * 2007-05-25 2008-12-18 Emergent Product Development Gaithersburg Inc. Chlamydia vaccine comprising htra polypeptides
US8703153B2 (en) 2008-06-16 2014-04-22 Prokarium Ltd. Salmonella vectored vaccines against Chlamydia and methods of use
EP2318515A4 (en) * 2008-08-06 2012-11-14 Emergent Product Dev Uk Ltd DIFFICULT CLOSTRIDIUM VACCINES, AND METHODS OF USE
US20120064114A1 (en) * 2008-10-21 2012-03-15 Emergent Product Development United Kingdom Use of e. coli surface antigen 3 sequences for the export of heterologous antigens
US8481052B2 (en) 2011-05-17 2013-07-09 Cj Cheiljedang Corporation Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same
JP2016535766A (ja) 2013-10-11 2016-11-17 セルヴィシオ ガレゴ デ サウデ（エスイーアールジーエーエス） 弱毒化生ワクチン
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
EP3922255A1 (en) 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
EP4124342A1 (en) 2021-07-28 2023-02-01 Prokarium Limited Cancer therapy with live attenuated bacteria
WO2023105076A1 (en) 2021-12-09 2023-06-15 Prokarium Limited Combination cancer therapy
WO2024061748A1 (en) 2022-09-21 2024-03-28 Prokarium Limited Salmonella strain with chromosomally integrated landing pad
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) * 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) * 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
NO794196L (no) * 1978-12-22 1980-06-24 Biogen Nv Fremgangsmaate ved fremstilling av et rekombinert dna molekyl
US4530901A (en) * 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US5210035A (en) * 1980-05-19 1993-05-11 Board Of Trustees Of Leland Stanford Jr. University Non-reventing live vaccines
US4550081A (en) * 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) * 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US5643579A (en) * 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US4810648A (en) * 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US5397697A (en) * 1989-01-10 1995-03-14 Ciba-Geigy Corporation Identification of plant-responsive genes of bacteria
FR2664614B1 (fr) 1990-07-11 1992-10-16 Pasteur Institut Sequences nucleiques issues du genome de salmonella typhi, et leurs utilisations notamment pour le diagnostic in vitro de la presence de bacteries du genre salmonella dans les produits alimentaires.
SE9101433D0 (sv) 1991-05-13 1991-05-13 Marianne Hansson Recombinant dna sequence and its use
WO1993004202A1 (en) 1991-08-22 1993-03-04 Washington University Polynucleotide probes for salmonella
WO1993007266A1 (en) * 1991-10-07 1993-04-15 Idaho Research Foundation, Inc. Genetic construct for selection of homologous recombinants on a single selective medium
AU3130893A (en) 1991-11-15 1993-06-15 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes
US5356797A (en) * 1991-11-15 1994-10-18 Board Of Regents, The University Of Texas Membrane expression of heterologous genes
JPH08503136A (ja) 1992-11-06 1996-04-09 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ Ｐ．ｍｕｌｔｏｃｉｄａによるパスツレラ症に対する感染防御剤
WO1994026933A1 (en) 1993-05-13 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Genetic footprinting: insertional mutagenesis and genetic selection
AU3958895A (en) 1994-10-18 1996-05-06 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes
NZ511170A (en) * 1994-12-09 2005-02-25 Imp College Innovations Ltd Administering anitgens for protection against Salmonella infections
US5700683A (en) * 1995-02-17 1997-12-23 Pathogenesis Corporation Virulence-attenuating genetic deletions deleted from mycobacterium BCG
WO1997014800A1 (en) * 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
WO1997018225A1 (en) 1995-11-14 1997-05-22 The General Hospital Corporation Salmonella secreted proteins and uses thereof
WO1998006428A1 (en) 1996-08-16 1998-02-19 The Uab Research Foundation Mucosal immunogens for novel vaccines
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
DE69828182T2 (de) 1997-02-14 2005-12-22 Merck & Co., Inc. Polynukleotid-impfstoff-formulierungen
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
GB9804809D0 (en) 1998-03-06 1998-04-29 Wallis Timothy S Attenuated salmonella:materials and methods relating thereto
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
AU5860599A (en) 1998-09-04 2000-03-27 Creatogen Aktiengesellschaft Attenuated salmonella spi2 mutants as antigen carriers
EP1129196B1 (en) * 1998-11-09 2008-01-09 Microscience Limited Virulence genes and proteins, and their use
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
EP1226254A2 (en) 1999-11-05 2002-07-31 L'Unité de Recherche en Biologie Moléculaire (URBM) des Facultés Universitaires Notre Dame de la Paix (FUNDP) Virulence genes, proteins, and their use
JP3414342B2 (ja) * 1999-11-25 2003-06-09 日本電気株式会社 集積回路チップの実装構造および実装方法
WO2001048208A2 (en) * 1999-12-23 2001-07-05 Vmax Limited Streptococcus pyogenes virulence genes and proteins and their use
GB0011108D0 (en) 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
GB0127657D0 (en) 2001-11-19 2002-01-09 Microscience Ltd Virulence genes and proteins and their use
US7449178B2 (en) * 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria

Also Published As

Publication number Publication date
NZ539260A (en) 2007-01-26
DE60043868D1 (de) 2010-04-01
AP2001002317A0 (en) 2001-12-31
OA11940A (en) 2006-04-12
CA2372553A1 (en) 2000-11-16
PT1183269E (pt) 2007-02-28
PL354355A1 (en) 2004-01-12
ZA200108912B (en) 2002-12-24
TR200702949T2 (tr) 2007-08-21
AU763898B2 (en) 2003-07-31
BRPI0010418B8 (pt) 2021-05-25
ATE346090T1 (de) 2006-12-15
US20080274139A1 (en) 2008-11-06
EA200101187A1 (ru) 2002-04-25
GB9910812D0 (en) 1999-07-07
CZ20014030A3 (cs) 2002-06-12
IL146255A0 (en) 2002-07-25
NO20015464D0 (no) 2001-11-08
MXPA01011477A (es) 2002-06-04
DK1183269T3 (da) 2007-04-02
WO2000068261A2 (en) 2000-11-16
NO329520B1 (no) 2010-11-01
BR0010418A (pt) 2003-07-22
IL186993A (en) 2010-02-17
JP2003509008A (ja) 2003-03-11
CN1177863C (zh) 2004-12-01
AU4593200A (en) 2000-11-21
WO2000068261A3 (en) 2001-02-08
DE60031974D1 (de) 2007-01-04
US6756042B1 (en) 2004-06-29
CZ301926B6 (cs) 2010-08-04
DE60031974T2 (de) 2007-03-15
MA25411A1 (fr) 2002-04-01
KR100811319B1 (ko) 2008-03-07
BR0010418B1 (pt) 2013-04-16
ATE457998T1 (de) 2010-03-15
KR20060101563A (ko) 2006-09-25
US20040191866A1 (en) 2004-09-30
AP1470A (en) 2005-09-26
HUP0201117A2 (en) 2002-08-28
EA004921B1 (ru) 2004-10-28
CN1360594A (zh) 2002-07-24
IL146255A (en) 2008-11-26
KR20020018193A (ko) 2002-03-07
EP1702927B1 (en) 2010-02-17
JP4583607B2 (ja) 2010-11-17
EP1183269A1 (en) 2002-03-06
CY1107656T1 (el) 2013-04-18
KR100680391B1 (ko) 2007-02-08
US7211264B2 (en) 2007-05-01
US7887816B2 (en) 2011-02-15
EP1183269B1 (en) 2006-11-22
CA2372553C (en) 2011-09-27
EP1702927A1 (en) 2006-09-20
NO20015464L (no) 2001-11-08
ES2277591T3 (es) 2007-07-16

Similar Documents

Publication Publication Date Title
AP2001002317A0 (en) Attenuated microorganisms for the treatment of infection
IL150048A0 (en) Enzyme treatment for infection
IL152553A0 (en) Compounds and methods for the treatment and prevention of bacterial infection
ZA200007642B (en) Treatment of airborne microorganisms.
ZA200108215B (en) Compositions and methods for treatment of staphylococcal infection.
HUP0200738A3 (en) Method of the treatment of incontinence
PL349347A1 (en) Novel treatment
NZ513686A (en) Treatment of trauma
HK1046913A1 (zh) 為治療傳染病的被縮小微生物
GB0025103D0 (en) Treatment of process fluids
GB9906372D0 (en) Effluent treatment plant
AU2003204710A1 (en) Attenuated microorganisms for the treatment of infection
AU2003304316A8 (en) Compounds and methods for the treatment and prevention of bacterial infection
GB2350301B (en) Appliance for medical treatment
GB2359073B (en) Fluid treatment
GB9924958D0 (en) Treatment of neuropathy
IL152925A0 (en) Treatment of neuropathy
GB9903558D0 (en) Medical treatment
GB9924583D0 (en) Sludge treatment
SI1220858T1 (en) Oxazinoquinolones useful for the treatment of viral infections
GB9923111D0 (en) Effluent treatment
ZA200204801B (en) Method of inactivating microorganisms.
GB9920788D0 (en) Novel treatment
GB9920787D0 (en) Novel treatment
GB9909650D0 (en) Novel treatment

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal